The Unregulated Probiotic Market

Clinical Gastroenterology and Hepatology

Volumn 17, Issue 5, 2019, Pages 809-817

  de Simone, Claudio ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Inflammatory Bowel Disease; Manufacturing; Probiotics; Regulation

Indexed keywords

BACTERIAL DNA; PROBIOTIC AGENT;

ANTIRETROVIRAL THERAPY; BACTERIAL STRAIN; BIFIDOBACTERIUM; CLINICAL EFFECTIVENESS; COLONY FORMING UNIT; DIET THERAPY; DIETARY INTAKE; FOOD INDUSTRY; FOOD SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATORY BOWEL DISEASE; LACTOBACILLUS; MARKETING; MUCORMYCOSIS; PRESCRIPTION; QUALITY CONTROL; REVIEW; SACCHAROMYCES BOULARDII; SAFETY; DIETARY SUPPLEMENT; DRUG CONTROL; HEALTH CARE POLICY; PROCEDURES;

DIET THERAPY; DIETARY SUPPLEMENTS; DRUG AND NARCOTIC CONTROL; HEALTH POLICY; HUMANS; PROBIOTICS;

EID: 85049302886     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2018.01.018     Document Type: Review

References (28)

1. Health and Nutrition Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria, 2001, World Health Organization and Food and Agriculture Organization of the United Nations, Rome.
2. Hill, C., Guarner, F., Reid, G., et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11 (2014), 506–514.
3. Benton, D., Williams, C., Brown, A., Impact of consuming a milk drink containing a probiotic on mood and cognition. Eur J Clin Nutr 61 (2007), 355–361.
4. World Gastroenterology Organisation Global Guidelines: Probiotics and Prebiotics, 2017, World Gastroenterology Organisation, Milwaukee, WI.
5. Magro, F., Gionchetti, P., Eliakim, R., et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohn's Colitis 11 (2017), 649–670.
6. Harbord, M., Eliakim, R., Bettenworth, D., et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: current management. J Crohns Colitis 11 (2017), 769–784.
7. Mikelsaar, M., Lazar, V., Onderdonk, A.B., et al. Do probiotic preparations for humans really have efficacy?. Microb Ecol Health Dis, 22, 2011, 10128.
8. Sanders, M.E., Merenstein, D.J., Ouwehand, A.C., et al. Probiotic use in at-risk populations. J Am Pharm Assoc 56 (2016), 680–686.
9. Sanders, M.E., Akkermans, L.M.A., Haller, D., et al. Safety assessment of probiotics for human use. Gut Microbes 1 (2010), 164–185.
10. Hazards, EPoB., Statement on the update of the list of QPS-recommended biological agents intentionally added to food or feed as notified to EFSA. 2: suitability of taxonomic units notified to EFSA until March 2015. EFSA J, 13, 2015, 4138.
11. New Dietary Ingredients Notification Process, 2016, U.S. Food and Drug Administration, Washington, DC.
12. Vallabhaneni, S., Walker, T.A., Lockhart, S.R., et al. Notes from the field: Fatal gastrointestinal mucormycosis in a premature infant associated with a contaminated dietary supplement–Connecticut, 2014. MMWR Morb Mortal Wkly Rep 64 (2015), 155–156.
13. Besselink, M.G., van Santvoort, H.C., Buskens, E., et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 371 (2008), 651–659.
14. Atıcı S., Soysal, A., Karadeniz Cerit, K., et al. Catheter-related Saccharomyces cerevisiae fungemia following saccharomyces boulardii probiotic treatment: in a child in intensive care unit and review of the literature. Med Mycol Case Rep 15 (2017), 33–35.
15. Martin, W.I., Tonner, R., Trivedi, J., et al. Saccharomyces boulardii probiotic-associated fungemia: questioning the safety of this preventive probiotic's use. Diagn Microbiol Infect Dis 87 (2017), 286–288.
16. Didari, T., Solki, S., Mozaffari, S., et al. A systematic review of the safety of probiotics. Expert Opin Drug Saf 13 (2014), 227–239.
17. d'Ettorre, G., Rossi, G., Scagnolari, C., et al. Probiotic supplementation promotes a reduction in T-cell activation, an increase in Th17 frequencies, and a recovery of intestinal epithelium integrity and mitochondrial morphology in ART-treated HIV-1-positive patients. Immun Inflamm Dis 5 (2017), 244–260.
18. Gutierrez, A., Zapater, P., Juanola, O., et al. Gut bacterial DNA translocation is an indipendent risk factor of flare at short term in patients with Crohn's disease. Am J Gastroenterol 111 (2016), 529–540.
19. Cinque, B., La Torre, C., Lombardi, F., et al. Production conditions affect the in vitro anti-tumoral effects of a high concentration multi-strain probiotic preparation. PLoS One, 11, 2016, e0163216.
20. Cinque, B., La Torre, C., Lombardi, F., et al. VSL#3 probiotic differently influences IEC-6 intestinal epithelial cell status and function. J Cell Physiol 232 (2017), 3530–3539.
21. Trinchieri, V., Laghi, L., Vitali, B., et al. Efficacy and safety of a multistrain probiotic depends from manufacturing. Front Immunol, 8, 2017, 1474.
22. European Food Standards Agency. Qualified Presumption of Safety (QPS). Available from: http://www.efsa.europa.eu/en/topics/topic/qualified-presumption-safety-qps. Accessed June 12, 2017.
23. Kolacek, S., Hojsak, I., Canani, R.B., et al. Commercial probiotic products: a call for improved quality control. A position paper by the ESPGHAN Working Group for Probiotics and Prebiotics. J Pediatr Gastroenterol Nutr 65 (2017), 117–124.
24. International Probiotics Association. Regulation of Probiotics in the USA: Dietary Supplements. 2016. Available from: http://internationalprobiotics.org/regulation-probiotics-usa/. Accessed September 30, 2016.
25. Guidance for Industry: Frequently Asked Questions About Medical Foods, Second Edition, 2016, U.S. Food and Drug Administration, Washington, DC.
26. Sanders, M.E., Shane, A.L., Merenstein, D.J., Advancing probiotic research in humans in the United States: challenges and strategies. Gut Microbes 7 (2016), 97–100.
27. Lee, J.F., Litten, J.B., Grampp, G., Comparability and biosimilarity: considerations for the healthcare provider. Curr Med Res Opin 28 (2012), 1053–1058.
28. Biagioli, M., Laghi, L., Carino, A., et al. Metabolic variability of a multispecies probiotic preparation impacts on the anti-inflammatory activity. Front Pharmacol, 8, 2017, 505.